[Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones]

Ter Arkh. 2008;80(10):21-6.
[Article in Russian]

Abstract

Aim: To study effects of avandia and its combination with metformine (avandamet) on secretion of fat tissue hormones.

Material and methods: The examination protocol for 42 patients with type 2 diabetes mellitus (DM) aged 62.4 +/- 7.7 years comprised tests for blood levels of leptin, soluble receptor to leptin, insulin, grelin, resistin and adiponectine.

Results: The treatment resulted in reduction of fasting glycemia from 10.69 +/- 2.54 to 8.42 +/- 1.73 mmol/l, of glycosilated hemoglobin--from 8.1 + 1.6 to 7.75%, immunoreactive insulin--from 19.1 +/- 8.3 to 12.0 +/- 6.5 mg/ml, grelin--from 21.7 +/- 14.6 to 17.3 +/- 13.7 mg/ml, leptin--from 40.3 +/- 24.2 to 26.9 +/- 15.4 mg/ml, soluble receptor to leptin--from 17.9 +/- 4.5 to 13.1 +/- 3.5 mg/ml. LDLP and HDLP cholesterol was high.

Conclusion: Avandia and avandamet are effective antidiabetic drugs with a beneficial effect on secretion of fat tissue hormones.

MeSH terms

  • Adiponectin / metabolism*
  • Adipose Tissue / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Drug Combinations
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Ghrelin / metabolism*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / metabolism*
  • Leptin / metabolism*
  • Male
  • Metformin / therapeutic use*
  • Middle Aged
  • Resistin / metabolism*
  • Rosiglitazone
  • Thiazoles / therapeutic use*
  • Thiazolidinediones / therapeutic use*

Substances

  • Adiponectin
  • Drug Combinations
  • Fibrinolytic Agents
  • Ghrelin
  • Hypoglycemic Agents
  • Insulin
  • Leptin
  • Resistin
  • Thiazoles
  • Thiazolidinediones
  • rosiglitazone-metformin combination
  • Rosiglitazone
  • Metformin